Tumor vessel normalization by chloroquine independent of autophagy

Cancer Cell

Volumn 26, Issue 2, 2014, Pages 190-206

  Maes, Hannelore ^a   Kuchnio, Anna ^b,c   Peric, Aleksandar ^c   Moens, Stijn ^b,c   Nys, Kris ^a   DeBock, Katrien ^b,c   Quaegebeur, Annelies ^b,c   Schoors, Sandra ^b,c   Georgiadou, Maria ^b,c   Wouters, Jasper ^b,d   Vinckier, Stefan ^b,c   Vankelecom, Hugo ^b   Garmyn, Marjan ^b   Vion, Anne Clémence ^e   Radtke, Freddy ^f,g   Boulanger, Chantal ^e   Gerhardt, Holger ^b,c,h   Dejana, Elisabetta ⁱ   Dewerchin, Mieke ^b,c   Ghesquière, Bart ^b,c   Annaert, Wim ^c   Agostinis, Patrizia ^a   Carmeliet, Peter ^b,c   more..

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^f EPFL   (Switzerland)

^g SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CISPLATIN; DACARBAZINE; NOTCH1 RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOSOME; ENDOTHELIUM CELL; HYPOXIA; IN VIVO STUDY; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; ANIMALS; AUTOPHAGY; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; DRUG SYNERGISM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, NOTCH1; SKIN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905706340     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.06.025     Document Type: Article

References (35)

1. Andersson E.R., Sandberg R., Lendahl U. Notch signaling: simplicity in design, versatility in function. Development 2011, 138:3593-3612.
2. Baron M. Endocytic routes to Notch activation. Semin. Cell Dev. Biol. 2012, 23:437-442.
3. Benedito R., Rocha S.F., Woeste M., Zamykal M., Radtke F., Casanovas O., Duarte A., Pytowski B., Adams R.H. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 2012, 484:110-114.
4. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
5. De Strooper B., Annaert W. Novel research horizons for presenilins and γ-secretases in cell biology and disease. Annu. Rev. Cell Dev. Biol. 2010, 26:235-260.
6. Dill M.T., Rothweiler S., Djonov V., Hlushchuk R., Tornillo L., Terracciano L., Meili-Butz S., Radtke F., Heim M.H., Semela D. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 2012, 142:967-977, e2.
7. Eichmann A., Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol. 2012, 24:188-193.
8. Fortini M.E. Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell 2009, 16:633-647.
9. Fung C., Lock R., Gao S., Salas E., Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol. Biol. Cell 2008, 19:797-806.
10. Guarani V., Deflorian G., Franco C.A., Krüger M., Phng L.K., Bentley K., Toussaint L., Dequiedt F., Mostoslavsky R., Schmidt M.H., et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011, 473:234-238.
11. Hagihara N., Walbridge S., Olson A.W., Oldfield E.H., Youle R.J. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res. 2000, 60:230-234.
12. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
13. Harrington L.S., Sainson R.C., Williams C.K., Taylor J.M., Shi W., Li J.L., Harris A.L. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc. Res. 2008, 75:144-154.
14. Huang Y., Yuan J., Righi E., Kamoun W.S., Ancukiewicz M., Nezivar J., Santosuosso M., Martin J.D., Martin M.R., Vianello F., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U S A 2012, 109:17561-17566.
15. Lee S.J., Silverman E., Bargman J.M. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat. Rev. Nephrol. 2011, 7:718-729.
16. Leite de Oliveira R., Deschoemaeker S., Henze A.T., Debackere K., Finisguerra V., Takeda Y., Roncal C., Dettori D., Tack E., Jönsson Y., et al. Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 2012, 22:263-277.
17. Li J.L., Sainson R.C., Shi W., Leek R., Harrington L.S., Preusser M., Biswas S., Turley H., Heikamp E., Hainfellner J.A., Harris A.L. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth invivo. Cancer Res. 2007, 67:11244-11253.
18. Liang X., De Vera M.E., Buchser W.J., Romo de Vivar Chavez A., Loughran P., Beer Stolz D., Basse P., Wang T., Van Houten B., Zeh H.J., Lotze M.T. Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res. 2012, 72:2791-2801.
19. Liu Z., Turkoz A., Jackson E.N., Corbo J.C., Engelbach J.A., Garbow J.R., Piwnica-Worms D.R., Kopan R. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J.Clin. Invest. 2011, 121:800-808.
20. Maes H., Rubio N., Garg A.D., Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol. Med. 2013, 19:428-446.
21. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
22. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
23. Müller C.S. Notch signaling and malignant melanoma. Adv. Exp. Med. Biol. 2012, 727:258-264.
24. Noman M.Z., Janji B., Kaminska B., Van Moer K., Pierson S., Przanowski P., Buart S., Berchem G., Romero P., Mami-Chouaib F., Chouaib S. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res. 2011, 71:5976-5986.
25. Oberlin E., El Hafny B., Petit-Cocault L., Souyri M. Definitive human and mouse hematopoiesis originates from the embryonic endothelium: a new class of HSCs based on VE-cadherin expression. Int. J. Dev. Biol. 2010, 54:1165-1173.
26. Peng Y.F., Shi Y.H., Ding Z.B., Ke A.W., Gu C.Y., Hui B., Zhou J., Qiu S.J., Dai Z., Fan J. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy 2013, 9:2056-2068.
27. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009, 16:196-208.
28. Radtke F., Wilson A., Stark G., Bauer M., van Meerwijk J., MacDonald H.R., Aguet M. Deficient Tcell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10:547-558.
29. Rouschop K.M., van den Beucken T., Dubois L., Niessen H., Bussink J., Savelkouls K., Keulers T., Mujcic H., Landuyt W., Voncken J.W., et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J.Clin. Invest. 2010, 120:127-141.
30. Sannerud R., Annaert W. Trafficking, a key player in regulated intramembrane proteolysis. Semin. Cell Dev. Biol. 2009, 20:183-190.
31. Townsend K.N., Hughson L.R., Schlie K., Poon V.I., Westerback A., Lum J.J. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol. Rev. 2012, 249:176-194.
32. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 2012, 12:401-410.
33. Xie X., White E.P., Mehnert J.M. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS ONE 2013, 8:e55096.
34. Yan M., Callahan C.A., Beyer J.C., Allamneni K.P., Zhang G., Ridgway J.B., Niessen K., Plowman G.D. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463:E6-E7.
35. Zhang J., Fukuhara S., Sako K., Takenouchi T., Kitani H., Kume T., Koh G.Y., Mochizuki N. Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin. J.Biol. Chem. 2011, 286:8055-8066.